This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.

Find out more about how we use cookies and how to manage them by reading our cookie notice.

Shalini Andersson PhD & David Blakey PhD

Head of CVMD iMed DMPK | Chief Scientist, Oncology iMed, AstraZeneca

Shalini is Senior Director and Head of Drug Metabolism & Pharmacokinetics within the Cardiovascular and Metabolic Disease Innovative Medicines unit (CVMD iMed) since December 2010. She is also a member of the Management Team for CVMD iMed as well as of the Review Board for CVMD projects.

Prior to this role, Shalini held several leadership roles within CVMD Medicinal Chemistry including Head of Enabling Technologies and Head of Lead Optimization focused on developing world class platforms for design, synthesis, purification and analysis of small molecules for Drug projects.

Shalini received her PhD in 1989 at the University of Linköping, Sweden and was a research fellow at the Institute of Pharmaceutical Chemistry, University of Münster, Germany.

Between 1990-1997 she held various research and teaching positions at the University of Linköping including Associate Professor in Organic and Analytical Chemistry. She joined AstraZeneca in 1997.She is the author or co-author of over 30 peer reviewed articles, 2 book chapters and 3 patents.

David: I have over 25 years experience in the Pharmaceutical industry discovering and developing therapeutic antibodies, small molecule and more recently oligonucleotides. After obtaining a degree in Biochemistry from Oxford University and a PhD in Drug Metabolism from London University I worked as a Post Doc on the optimisation and pharmacology of ricin immunotoxins at the ICRF in London. In 1987 I joined AstraZeneca where I initially worked on the development of early generation antibody therapeutics as well as leading small molecule drug projects. For a number of years I also had a science leadership role within AstraZeneca in the area of therapeutic vascular modulation having championed the area within the company. More recently I championed the establishment and scientific management of AstraZeneca’s first major antibody collaboration with Abgenix/Amgen that led to a number of clinical development candidates. In my current role as Chief Scientist in the Oncology iMed I have leadership roles in evaluation of new approaches and technologies. Over the last few years I led a global cross therapy area team on oligonucleotide based therapies and championed the area to senior management within AZ. I currently have leadership roles in collaborations with ISIS, Regulus and Moderna and spend the majority of my time supporting and championing the oligoncleotide area within AZ. I have over 50 peer reviewed publications where I am lead or co-author and have published and presented on my work at conferences throughout my career at AstraZeneca.

You are viewing: All posts Reset filters

Our Other Authors